Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

Official data shows that since 2019, this medication has been linked to 23 deaths and 1,179 serious adverse reactions in the ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

New diet drugs are making it easier to lose weight. So does that mean we can stop exercising? Health experts say no. There is ...

Notre Dame's schedule is chock-full of wins, but there is a blemish on the mark. The Fighting Irish's lone loss came against the Northern Illinois Huskies all the way back in early September ...